← brief for 2026-10-25 · Slowing decline

Clinical Trial of Tolvaptan in Pediatric ADPKD: Two-Year, Open-Label Extension.

Article B Peer reviewed Small trial

Key takeaways

This is a follow-up to a trial of a drug called tolvaptan. The drug is used for a genetic kidney disease. This part of the study lasted two years. It looked at safety and kidney function in children. The study was small, involving only the children who finished the first part of the trial.

Who did this work

Mekahli D · Guay-Woodford LM · Cadnapaphornchai MA · Greenbaum LA · Litwin M · Seeman T · Dandurand A · Zhang Z · Sikes K · Shoaf SE · Schaefer F · Pediatric Trial Investigators13

Source

Article · PubMed, Climate, heat and the kidney · 2026 Sep 15
https://pubmed.ncbi.nlm.nih.gov/42923342/